

# HERMES

<b><u>INVESTIGATORS</u></b>	<ul style="list-style-type: none"><li>• Viviana Navas, MD Principal Investigator</li><li>• Hany Elmahdy, MD Sub-Investigator</li><li>• Edward Shmukler, MD Sub-Investigator</li></ul>
<b><u>Trial Objective</u></b>	<ul style="list-style-type: none"><li>• This is an interventional, randomised, parallel-group, double-blind, placebo-controlled, multicentre, multi-national cardiovascular outcomes trial (CVOT) designed to evaluate the effects of ziltivekimab 15 mg versus placebo (randomised 1:1), both administered s.c. once-monthly and added to standard of care, on morbidity and mortality of participants with heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or HF with preserved ejection fraction (HFpEF) and systemic inflammation.</li></ul>
<b><u>Randomization</u></b>	<ul style="list-style-type: none"><li>• Randomized 1:1 (Ziltivekimab vs. Placebo)</li></ul>
<b><u>Key Inclusion</u></b>	<ul style="list-style-type: none"><li>• Diagnosis of Heart Failure (NYHA Class II-IV)</li><li>• LVEF &gt;40% documented by echocardiography within 12 months prior to or a screening</li></ul>
<b><u>Key Exclusion</u></b>	<ul style="list-style-type: none"><li>• Left Ventricular Assist Device (LVAD) implantation or heart transplantation</li><li>• Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including COPD</li></ul>